Topics

Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

14:16 EDT 7 Oct 2019 | SCRIP

Company’s Phase III program is attempting to replicate Phase II efficacy data showing superiority for curing Clostridium difficile infections and...

      

Related Stories

 

Original Article: Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff

NEXT ARTICLE

More From BioPortfolio on "Summit Looking To Secure Superiority Claim For Ridinilazole Over Vancomycin In C. Diff"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Clostridium difficile (CDI)
A clostridium difficile infection (CDI) is a type of bacterial infection that can affect the digestive system. It most commonly affects people who are staying in hospital.  The symptoms of CDI can range from mild to severe and include: diarrhoe...